title: A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
abstract: In this multicentre, double-blind study, patients with LUTS/BPH were randomised to 26 weeks with finasteride 5 mg once daily (n=204) or tamsulosin 0.4 mg once daily (n=199). Double-blind treatment was continued for another 26 weeks (total treatment duration: 1 y). The primary efficacy parameter was the difference in mean change in total Symptom Problem Index (SPI) from baseline to end point at week-26 in the intention-to-treat (ITT) and per protocol (PP) populations. Tamsulosin induced a greater improvement in total SPI (-5.2 points or -37%) compared to finasteride (-4.5 points or -31%) at week-26 (P=0.055 in ITT and P=0.032 in PP). Tamsulosin improved urinary symptoms (particularly the more bothersome storage symptoms) and flow more quickly than finasteride. The difference was statistically significant for the SPI from week-1 (reduction, respectively, -2.5 vs -1.8 points, P=0.043) to week-18 and for Qmax from week-1 (increase, respectively, 2.3 vs 0.7 ml/s, P=0.0007) to week-12. Both treatments were well tolerated with a comparable incidence of adverse events, including urinary retention.
authors.affiliation: Università Vita-Salute S Raffaele, Milan, Italy. rigatti.patrizio@hsr.it
authors.forename: P
authors.initials: P
authors.lastname: Rigatti
authors.forename: M
authors.initials: M
authors.lastname: Brausi
authors.forename: R M
authors.initials: RM
authors.lastname: Scarpa
authors.forename: D
authors.initials: D
authors.lastname: Porru
authors.forename: H
authors.initials: H
authors.lastname: Schumacher
authors.forename: C A
authors.initials: CA
authors.lastname: Rizzi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D018120:Finasteride / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012725:Sexual Behavior / Q000187:drug effects; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000077409:Tamsulosin; D014555:Urination Disorders / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D013449:Sulfonamides; D018120:Finasteride; D000077409:Tamsulosin